Ribon is developing a new generation of first-in-class therapeutics targeting novel enzyme families, which are activated under cellular stress conditions that contribute to disease. Our scientific founders are leaders in the field behind many landmark discoveries that have ushered in better understanding of molecular action and biological function of these enzyme classes, beginning with monoPARPs. By combining deep insights from our founders and experienced management team, Ribon is building a proprietary drug discovery platform to leverage these discoveries and benefit patients.

Join our team of experts.
Find Out More